Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 21, Issue 3, 2008, Pages 309-319

  Petzold, Ursula ^a,d   Kremer, Hans Joachim ^b   Nguyen, Duc Tung ^a   Munzel, Ullrich ^a   Dietrich, Hartmut ^c   Maus, Joachim ^a  

^a MEDA Pharma GmbH and Co KG   (Germany)

^b Medical Writing Service   (Germany)

^c ClinPharmCologne   (Germany)

^d NONE   (Germany)

Author keywords

Formoterol; Inhaled; Pharmacodynamics; Pharmacokinetics

Indexed keywords

FORMOTEROL; GLUCOSE; POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; DRY POWDER; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; POTASSIUM BLOOD LEVEL; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; YOUNG ADULT;

EID: 54949146110     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0690     Document Type: Article

References (22)

1. Drugdex monography formoterol. Micromedex Drugdex® 03/2004.
2. Faulds D, Hollingshead LM, Goa KL: Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991;42:115-137.
3. Bartow RA, Brogden RN: Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998;55:303-322.
4. Cheer SM, Scott LJ: Formoterol. A review of its use in chronic obstructive pulmonary disease. Am J Respir Med. 2002;1:285-300.
5. GINA Report. Global strategy for asthma management and prevention. Revised 2006. www.ginasthma.org
6. Fachinformation Foradil® P. Novartis Pharma, Fach-Info-Service, update 02/2006.
7. Siddiqui MA, Plosker GL: The Novolizer: a multidose dry powder inhaler. Treat Respir Med. 2005;4:63-69.
8. Derks MGM, van den Berg BTJ, van den Zee JS, Braat MCP, van Boxtel CJ: Pharmacokinetics/pharmacodynamics of inhaled formoterol. Netherlands J Med. 1995;36: A54 (abstract 24).
9. Derks MGM, van den Berg BTJ, van der Zee JS, Braat MCP, van Boxtel CJ: Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemia effects and inhibition of allergic reactions. J Pharmacol Exp Ther. 1997;283:824-832.
10. Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G: Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol. 1999;55:131-138.
11. Marzo A, Monti CN, Tettamanti RA, Crivelli F, Bo LD, Mazzucchelli P, Meoli A, Pezzuto D, Corsico A: Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data. Arzneim Forsch/Drug Res. 2000;50:559-563.
12. Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R: Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007;1β1:1931-1941.
13. Snell NJ, Ganderton D: Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Respir Med. 1999;93:123-133.
14. Derendorf H, Hochhaus G, Mollmann H: Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med. 2001;14(Suppl 1):S9-S17.
15. European Pharmacopoeia: Inhalanda. Edition 5.1, p. 2843.
16. IPAC-RS DDU. Debating the operating curves for DDU tests on marketed inhalers. Industry's problem with the current FDA DDU requirements. 27 April 2004. www.fda.gov/ohrms/dockets/ac/03/slides/3996S1_09_Golden.PPT
17. Lipworth BJ, Clark DJ: Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. Eur J Clin Pharmacol. 1997;53:47-49.
18. Agertoft L, Pedersen S: Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler in children. Am J Respir Crit Care Med. 2003;168:779-782.
19. Selroos O, Borgstrom L, Ingelf J: Performance of turbuhaler(( R)) in patients with acute airway obstruction and COPD, and in children with asthma: understanding the clinical importance of adequate peak inspiratory flow, high lung deposition, and low in vivo dose variability. Treat Respir Med. 2006;5:305-315.
20. Scheinin M, Koulu M, Laurikainen E, Allonen H: Hypokalemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol. 1987;24:645-653.
21. Haalboom JRE, Deenstra M Struyvenberg A: Hypokalemia induced by inhalation of fenoterol. Lancet 1985;1:1125-1127.
22. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE: Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000;55:650-656.